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No speed limit now for publication of research in
Mediators of Inflammation
While research on inflammation processes
continues to be an expanding branch within the life
sciences there has been a spectacular growth within
the field of mediators. Mediators constitute the
fundamental network of signal and effector
molecules of communication between cells partici-
pating in the events of inflammation. We anticipate
that the bidirectional communication between the
immune and the nervous system will also prove to
involve mediators. Furthermore these molecules
represent important targets for the development of
drugs which could be applied in the treatment of
inflammatory disorders. Accordingly, Mediators of
Inqammation is of interest to those researchers
involved in cell biology, immunology, pharma-
cology, clinical sciences and the pharmaceutical
industry.
While not neglecting any of the earlier known
mediators (such as histamine, bradykinin, prosta-
glandins, leukotriences and PAF), Mediators of
I&gammation welcomes original articles on cyto-
kines (tumour necrosis factors, interleukins, inter-
ferons), evasive molecules e.g., nitric oxide, the
family of cell adhesion promoting molecules and
the biological response modifiers. Priority of
publication will be given to articles in which there
is emphasis on interactions between various classes
of mediators. Articles dealing with pharmacological
influences on mediators of inflammation will be
particularly welcome.
From the viewpoint of pathophysiology of
inflammatory disorders there is an intriguing
question: should mediators be counteracted or, by
contrast, can they be utilised as therapeutic agents?
We faced a similar problem 10 years ago in that in
immunoinflammatory conditions prostaglandin E2
exerts a two-fold function, i.e., reinforcement of the
vascular inflammatory components and inhibitory
modulation of macrophage-mediated immuno-
logical events. This functional dualism of prosta-
glandin E2 was reminiscent of Janus, the ancient
Roman diety, traditionally depicted with two faces.
Occasionally artists have shown the faces in a way
which reflects both hostility and benevolence. The
analogy with prostaglandin E2 appeared strong,
because this mediator was shown to exert both
harmful and beneficial functions. While some
aspects of this concept appeared speculative, not
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only is the evidence in favour of it now firm, but
recent findings indicate that the essentials of
simultaneously being a major culprit and. a
physiologically beneficial regulator can be extended
to other mediators of inflammation. Examples are
represented by the efforts of counteracting
interleukin-1 or tumour necrosis factor in some
clinical conditions and by recent trials in harnessing
their beneficial functions in other disorders. The
functional dualism is likely to be valid for several
mediators of inflammation. This, in fact prompted
us to chose Janus the par excellence symbol of
dualism as the logo for Mediators of lnjqammation.
Because dualisms is by definition controversial we
welcome articles which, while being based on sound
experiments, will provoke counteropinions from
colleagues.
Introduction and development ofnew techniques
have opened up unexplored areas in mediator
research, making it possible to study molecular
biological processes and their clinical impact which
were until not beyond experimental approach.
However the imbalance between the application of
ultramodern high-speed technology in research and
lack of application of such technology in publishing
these achievements, hampers the communication
between workers within the fields. Mediators of
Injqammation sets out to surmount the imbalance
between speed of research and delay in appearance
of the article. Reduction in publication time will be
achieved by exploitation of modern (i.e. electronic)
communication techniques between authors,
editors (peer reviewers) and the Publisher.
While speed of publication will be a prime feature
of Mediators of In)qammation, the highest standards
(i.e. novelty and reliability of results) will also be
ensured, through rigorous refereeing by inter-
nationally renowned authorities within the field.
With learned journals reviewing is, often very slow,
because referees usually do this work in their spare
time. Mediators of Inqammation rejects this practice.
The members of the team of the Editorial Board,
all eminent scientists in their field, have been
appointed having obtained their consent to be ready
to return evaluation of papers within a fortnight.
Hence authors will be assured of rapid and
high-quality reviewing.
Mediators of Injqammation aims to publish papers
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within 3 months of acceptance. Even exploiting the
above described principles, this short publication
time cannot be achieved without the co-operation
of the authors who are required to follow precisely
the Instructions to Authors which appears
elsewhere in this issue. Furthermore with papers
requiring revision, the manuscript will need to be
returned within a week.
Mediators of Inqammation feels challenged to meet
these goals. By achieving them it aims to shortly
become the rapid forum of prime choice within the
field. Also on behalf of my colleague B. Boris
Vargaftig, we urge you and your co-workers to
contribute the latest and best of your results and
thus back our new venture.
Ivan L Bonta
Editor-in-Chief
4 Mediators of Inflammation. Vol 1992